Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

Lk, Kastrukoff; Dr, McLean; Ta, McPherson

doi:10.1017/s0317167100024513

Cited by 12 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of these studies are difficult to interpret. Controlled trials have failed to demonstrate a convincing therapeutic effect of ALS in multiple sclerosis (Kastrukoff et al 1978, Mertin et al 1980, and there is no evidence that acute ulcerative colitis improves as a result of treatment with ALS (Heyworth &Truelove 1980,1981.…”

Section: Other Diseasesmentioning

confidence: 99%

Clinical Experience with Antilymphocyte Serum

Heyworth

1982

Immunological Reviews

View full text Add to dashboard Cite

Many different antilymphocytic antisera have been used clinically, and the properties of any particular type of ALS are not necessarily identical to those of any other type. Nevertheless, it is possible to draw certain general conclusions about the effects of ALS in human subjects. ALS administration has often been shown to reduce the number of circulating E-rosette-positive lymphocytes, although the precise mechanisms by which this reduction occurs are not known. Using a combined technique of E-rosette formation and immunofluorescence, heterologous immunoglobulin has been demonstrated on T and non-T lymphocytes from patients receiving non-selective ALS. Fifteen years' experience has failed to provide convincing support for the view that ALS (including immunoglobulin prepared from the whole antiserum) prolongs human renal allograft survival. It is not yet known whether ALS is a useful immunosuppressive agent in cardiac transplantation. One observation of possible clinical interest is that bone marrow regeneration has occurred in a number of patients with aplastic anemia who have been treated with ALS. No satisfactory method has been developed for monitoring the dose of ALS in human subjects. Appropriate studies may determine whether monoclonal antilymphocytic antibodies are clinically useful, for example in prolonging the survival of transplanted organs, in preventing or treating graft-versus-host disease, or in treating lymphoma, leukemia, or aplastic anemia.

show abstract

Section: Other Diseasesmentioning

confidence: 99%